REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
11.64
+0.04 (0.34%)
Nov 13, 2025, 4:00 PM EST - Market closed
REGENXBIO Employees
REGENXBIO had 353 employees as of December 31, 2024. The number of employees increased by 9 or 2.62% compared to the previous year.
Employees
353
Change (1Y)
9
Growth (1Y)
2.62%
Revenue / Employee
$456,992
Profits / Employee
-$504,008
Market Cap
589.25M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 353 | 9 | 2.62% |
| Dec 31, 2023 | 344 | -57 | -14.21% |
| Dec 31, 2022 | 401 | 29 | 7.80% |
| Dec 31, 2021 | 372 | 66 | 21.57% |
| Dec 31, 2020 | 306 | 49 | 19.07% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RGNX News
- 7 days ago - REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights - PRNewsWire
- 14 days ago - REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program - PRNewsWire
- 15 days ago - REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights - PRNewsWire
- 4 weeks ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 5 weeks ago - REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting - PRNewsWire
- 5 weeks ago - REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD - PRNewsWire
- 6 weeks ago - REGENXBIO Announces Presentation at the World Muscle Society - PRNewsWire